Effects of vagus nerve stimulation for Parkinson’s disease.

Share on facebook
Share on twitter
Share on google
Share on linkedin
Share on email
Share on print

Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson’s disease.

Abstract
BACKGROUND: Vagus nerve stimulation (VNS) modifies brain rhythms in the locus coeruleus (LC) via the solitary nucleus. Degeneration of the LC in Parkinson’s disease (PD) is an early catalyst of the spreading neurodegenerative process, suggesting that stimulating LC output with VNS has the potential to modify disease progression. We previously showed in a lesion PD model that VNS delivered twice daily reduced neuroinflammation and motor deficits, and attenuated TH-positive cell loss.
OBJECTIVE: The goal of this study was to characterize the differential effects of three clinically-relevant VNS paradigms in a PD lesion model.
METHODS: Eleven days after DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine, noradrenergic lesion, administered systemically)/6-OHDA (6-hydroxydopamine, dopaminergic lesion, administered intrastriatally) rats were implanted with VNS devices, and rats received either low-frequency VNS, standard-frequency VNS, or high-frequency microburst VNS. After 10 days of treatment and behavioral assessment, rats were euthanized, right prefrontal cortex (PFC) was dissected for norepinephrine assessment, and the left striatum, bilateral substantia nigra (SN), and LC were sectioned for immunohistochemical detection of catecholamine neurons, α-synuclein, astrocytes, and microglia.
RESULTS: At higher VNS frequencies, specifically microburst VNS, greater improvements occurred in motor function, attenuation of TH-positive cell loss in SN and LC, and norepinephrine concentration in the PFC. Additionally, higher VNS frequencies resulted in lower intrasomal α-synuclein accumulation and glial density in the SN.
CONCLUSIONS: These data indicate that higher stimulation frequencies provided the greatest attenuation of behavioral and pathological markers in this PD model, indicating therapeutic potential for these VNS paradigms.

PMID: 32629028 [PubMed – as supplied by publisher]

Brain Stimul. 2020 Jul 03;:

Authors: Farran A, Verner R, McGuire R, Helke K, Hinson V, Boger H

Join Our Newsletter


Mike

Mike

Comments?